| abstract |
The thienopyridinone compound of Formula (I) and its pharmaceutically acceptable salts are described; in these compounds, one of X1; X2 and X3 is S and the other two are each independently CR, where R and other variables are as defined herein; the compounds are shown to inhibit HPK1 kinase activity and have anti-tumor activity in vivo; The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as inhibition of the control point or tryptophan oxidation inhibitors. (see Formula). |